BioCertica, a trailblazer in African genetic testing and polygenic risk scoring (PRS), is proud to announce the closure of a $2.2 million Seed funding round, over-subscribed and led by Pronexus Venture Fund. This milestone is a testament to the growing interest in innovative healthcare solutions and marks a significant expansion phase for BioCertica.
In a significant strategic move, BioCertica has entered into an international co-selling agreement with Thermo Fisher, one of the world's largest genetic sequencing companies. This partnership will see Thermo Fisher selling BioCertica's solutions internationally to Laboratories and genetic testing centers greatly extending the company's reach and impact in Africa and the global healthcare market.
Furthering its growth, BioCertica extends its B2B white-labeled solutions to key international markets, including GCC and Turkey. This expansion underscores the company's commitment to transforming healthcare globally.
The Seed Round's success was bolstered by an I3 Innovation Grant from the Bill and Melinda Gates Foundation. This grant, alongside the support from Pronexus and other investors, underlines the innovative potential and global appeal of BioCertica's approach to personalized healthcare.
BioCertica has garnered significant international recognition, including being featured in GenomeWeb New York for introducing PRS methodology, the first of its kind in Africa - and has received multiple accolades, such as being named one of the Top 10 startups in South Africa (Innovation City 2022), winning the International Venture Academy in Finland (2022), and securing the most innovative product award at Bosnia-Herzegovina Engineering Week (2022). Additionally, BioCertica was nominated as one of the top 15 African Healthtech startups by VivaTech, Deloitte, and the IFC (International Finance Corporation) in 2023.
Gert van Wyk, BioCertica's founder and CEO, expresses his vision, "With the support of Pronexus and validation from the Bill and Melinda Gates Foundation, through the I3 program, we are set to redefine the landscape of precision medicine. This investment fuels our technological advancements and reinforces our mission to deliver personalized healthcare solutions in Africa and on a global stage."
Niël van Staden of Pronexus Venture Fund comments, "Our investment in BioCertica is rooted in a shared vision of innovating healthcare through technology. We are excited to be part of BioCertica's journey in transforming the future of health in Africa and beyond."
BioCertica's array of DNA test kits encompasses numerous health and wellness aspects, reflecting the company's commitment to user privacy and data security. These offerings empower clients with actionable genetic insights, supporting healthier lifestyle choices through a hyper-personalised platform.